Abstracts tagged "longitudinal studies"

Abstract Number: 1303 • 2013 ACR/ARHP Annual Meeting
Variations In Disease Activity and Therapeutic Management Of Rheumatoid Arthritis In Different International Regions: A Comparison Of Data From The Corrona International and Corrona United States Registries
Dimitrios A. Pappas¹, Kathy Lampl², Joel M. Kremer³, Sebastião C. Radominski⁴, Janos Gal⁵, Fredrik Nyberg⁶, Anand N. Malaviya⁷, Aimée Whitworth⁸, Oscar Luis Rillo⁹, Allan Gibofsky¹⁰, Tatiana Popkova¹¹, Meilien Ho¹², Ieda Laurindo¹³, George W. Reed⁸, Eduardo Mario Kerzberg¹⁴, Laura Horne¹⁵, Roman Záhora¹⁶, Katherine C. Saunders¹⁷, Bernado Pons-Estel¹⁸, Alina U. Onofrei¹⁹ and Jeffrey D. Greenberg²⁰, ¹Columbia University, New York, NY, ²AstraZeneca R&D Wilmington, Wilmington, DE, ³Center for Rheumatology, Albany Medical College, Albany, NY, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵Rheumatology, County Hospital, Kecskemet, Hungary, ⁶AstraZeneca R&D, Mölndal, Sweden, ⁷Rheumatology, Consultant Rheumatologist, ISIC Superspeciality Hospital, New Delhi-11007-, India, ⁸CORRONA, Inc., Southborough, MA, ⁹Hospital Tornú, Capital Federal, Argentina, ¹⁰Medicine and Public Health, Hospital for Special Surgery, New York, NY, ¹¹Research Institute of Rheumatology -Russian Academy of Medical Science, Moscow, Russia, ¹²AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ¹³Rheumatology, Universidade de São Paulo, São Paulo, Brazil, ¹⁴Rheumatology, J. M. Ramos Mejía Hospital, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina, ¹⁵AstraZeneca, Wilmington, DE, ¹⁶Revmatologická ambulance, Terezin, Czech Republic, ¹⁷Corrona, LLC., Southborough, MA, ¹⁸Hospital Provincial de Rosario, Rosario, Argentina, ¹⁹University of Massachusetts Medical School, Worcester, MA, ²⁰Rheumatology, NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: The CORRONA International (C.Intl) rheumatoid arthritis (RA) registry is the first multinational RA registry uniformly collecting baseline and longitudinal data. We explored variations in…
Abstract Number: 1271 • 2013 ACR/ARHP Annual Meeting
Longitudinal Disease Trajectory Of Juvenile Dermatomyositis
Lily Siok Hoon Lim^1,2, Eleanor Pullenayegum³, Dafna D. Gladman⁴, Earl D. Silverman⁵ and Brian M. Feldman⁶, ¹Pediatric Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ²Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, ON, Canada, ³Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: 1) To determine the longitudinal disease activity trajectory of an inception cohort of Juvenile Dermatomyositis (JDM) patients, 2) To identify predictor(s) for longitudinal disease…
Abstract Number: 1232 • 2013 ACR/ARHP Annual Meeting
Osteoporosis In Rheumatoid Arthritis – Still a Threat In The Biologic Era?
Glenn Haugeberg¹, Torhild Garen², Hege Sommerseth³, Anne Prøven³ and Knut Helgetveit³, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ³Rheumatology, Martina Hansens Hospital, Bærum, Norway
Background/Purpose: Osteoporosis is a well-known extra articular manifestation in rheumatoid arthritis (RA). In RA biologic disease modifying anti rheumatic drugs (DMARDs) has been shown to…
Abstract Number: 1008 • 2013 ACR/ARHP Annual Meeting
Longitudinal Analysis Of Direct Medical Costs For Systemic Sclerosis Patients: A Population-Based Study
Natalie McCormick¹, Carlo A. Marra², Eric C. Sayre³ and J. Antonio Avina-Zubieta⁴, ¹Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Pharm Sciences, Univ of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada
Background/Purpose: Patients with systemic sclerosis (SSc) have considerable morbidity which may be associated with high health resource utilization. Studies on health use and costs are…
Abstract Number: 901 • 2013 ACR/ARHP Annual Meeting
Smokers and Overweight Persons Are At Increased Risk Of New Onset Of Severe Foot Pain and Persistent Severe Foot Pain In a Population Study
Alyssa B. Dufour¹, Hylton B. Menz², Arunima Awale³, Thomas J. Hagedorn³, Virginia A. Casey³, Patricia P. Katz⁴ and Marian T. Hannan⁵, ¹Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School & Beth Israel Deaconess Medical Center, Boston, MA, ²Lower Extremity and Gait Studies Program, La Trobe University, Bundoora, Victoria 3086, Australia, ³Institute for Aging Research, Hebrew SeniorLife, Boston, MA, ⁴Medicine, University of California, San Francisco, San Francisco, CA, ⁵Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Few studies have evaluated risk factors for patterns of foot pain in the general population, let alone over time. An understanding of the possible…
Abstract Number: 882 • 2013 ACR/ARHP Annual Meeting
Association Of a Neutrophil Gene Signature Comprised Of Low Density Granulocyte (LDG)-Enriched Genes With Both Future Systemic Lupus Erythematosus Disease Activity and Poor Longterm Outcomes
Michelle Petri¹, Laurence S. Magder², Hong Fang¹, Jadwiga Bienkowska³, Andrea Dearth⁴, Norm Allaire⁵ and Ann Ranger⁴, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁴Biogen Idec Inc, Cambridge, MA, ⁵Biogen Idec Inc., Cambridge, MA
Background/Purpose: Neutrophils and neutrophil death (NETosis) have a role in the pathogenesis of SLE. A neutrophil gene signature (NGS) exists in SLE, although its association…
Abstract Number: 739 • 2013 ACR/ARHP Annual Meeting
Cardiac Involvement In Granulomatosis With Polyangiitis
Lucy McGeoch¹, Simon Carette², David Cuthberston³, Gary S. Hoffman⁴, Nader A. Khalidi⁵, Curry L Koening⁶, Carol A. Langford⁷, Paul A. Monach⁸, Larry W. Moreland⁹, Philip Seo¹⁰, Ulrich Specks¹¹, Steven R. Ytterberg¹², Carol McAlear¹³, Peter A Merkel¹⁴, Christian Pagnoux² and The Vcrc¹⁵, ¹Vasculitis clinic, Division of rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ³Biostatistics, University of South Florida, Tampa, FL, ⁴Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁵Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ⁷Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology, Boston University, Boston, MA, ⁹Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁰Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹¹Mayo Clinic, Rochester, MN, ¹²Rheumatology Division, Mayo Clinic, Rochester, MN, ¹³University of Pennsylvania, Philadelphia, PA, ¹⁴Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ¹⁵University of Pennsylvania and VA Medical Center, Philadelphia, PA
Background/Purpose: Prior cohort studies in Europe have found cardiac involvement to be rare in granulomatosis with polyangiitis (GPA) but associated with significant increases in mortality…
Abstract Number: 2514 • 2012 ACR/ARHP Annual Meeting
Racial/Ethnic Trends in Incidence and Prevalence of Rheumatoid Arthritis in a Large Multi-Ethnic Managed Care Population
Aniket A. Kawatkar¹, Cecilia Portugal¹, Li-Hao Chu² and Rajan Iyer³, ¹Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, ²Department of Research and Evaluation,, Kaiser Permanente Southern California, Pasadena, ³Department of Research and Evaluation,, Kaiser Permanente Southern California, Pasadena, CA
Background/Purpose: As epidemiologic studies throughout the world have shown significant variations, we sought to characterize racial differences in longitudinal epidemiologic trends of adult rheumatoid arthritis…
Abstract Number: 448 • 2012 ACR/ARHP Annual Meeting
Sustained and Cumulated Response Over Time in Rheumatoid Arthritis Patients Treated with Rituximab After Initial Failure of Anti Tumor Necrosis Factor Agents
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴ and Mihai Bojinca⁵, ¹Internal Medicine, Cantacuzino Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Clinic Hospital "Sf. Maria", Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania, ⁵Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania
Background/Purpose: Although anti-TNF therapies moved forward the treatment of rheumatoid arthritis (RA), failure of the first anti-TNF medication is not uncommon. Many times modifying dosage/frequency…
Abstract Number: 2490 • 2012 ACR/ARHP Annual Meeting
Herpes Zoster and Tofacitinib Therapy in Patients with Rheumatoid Arthritis
K. L. Winthrop¹, H. Valdez², E. Mortensen³, R. Chew⁴, S. Krishnaswami⁵, T. Kawabata⁵ and R. Riese⁴, ¹Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, ²Pfizer Inc., New York, NY, ³Global Medical Affairs, Pfizer Inc., Collegeville, PA, ⁴Pfizer Inc., Groton, CT, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Patients (pts) with RA are at increased risk for herpes zoster (HZ) i.e. ‘shingles'. Tofacitinib, a novel oral Janus kinase inhibitor investigated as a…
Abstract Number: 449 • 2012 ACR/ARHP Annual Meeting
Rituximab After First Anti Tumor Necrosis Factor Failure Is More Efficient with High Impact in Reducing Time and Costs to Achieve Superior Rates of Low Disease Activity and Remission
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴ and Mihai Bojinca¹, ¹Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania
Background/Purpose: Significant steps were done in creating new medications for treatment of rheumatoid arthritis (RA). As RA seriously affects the patients’ quality of life, the…
Abstract Number: 2469 • 2012 ACR/ARHP Annual Meeting
A Virtual Knee Joint Replacement Clinical Endpoint Based On Longitudinal Trends and Thresholds in Koos Knee Pain and Function in Osteoarthritis Initiative Participants
Robert M. Boudreau¹, David J. Hunter², Zhijie Wang³, Frank Roemer⁴, Felix Eckstein⁵, Michael J. Hannon³, Ali Guermazi⁶ and C. Kent Kwoh⁷, ¹Epidemiology, University of Pittsburgh, Pittsburgh, PA, ²Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ³Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴Radiology, Boston University School of Medicine, Boston, MA, ⁵Anatomy & Musculoskeletal Research, Paracelsus Medical University, Salzburg, Austria, ⁶Boston University, Boston, MA, ⁷School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Knee joint replacement (KR) is a cost-effective procedure with good long-term outcomes, but has limitations as an endpoint in OA intervention trials. A definition…
Abstract Number: 390 • 2012 ACR/ARHP Annual Meeting
Performance of Criteria for Remission in a Long-Term Observational Study of Patients with Early Rheumatoid Arthritis
Bjorn Svensson¹, Maria LE Andersson², Sidona-Valentina Bala³, Kristina Forslind⁴ and Ingiäld Hafström⁵, ¹Section of Rheumatology, Institution of Clinical Science, Lund University, Lund, Sweden, ²R&D Center, Spenshult Hospital, Oskarström, Sweden, ³Department of Health Sciences,, Lund University, Lund, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, ⁵Unit of Rheumatology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Remission is widely accepted as the goal of treatment in RA and has to be sustained to keep joint damage at a minimum (Smolen…
Abstract Number: 2158 • 2012 ACR/ARHP Annual Meeting
Baseline Folate Related Biomarkers in Serum and erythrocytes Are Not Associated with Methotrexate Response and Adverse Events in Rheumatoid Arthritis
Maurits C.F.J. De Rotte¹, Saskia M.F. Pluijm², Maja Bulatovic³, Johanna M.W. Hazes⁴ and Robert De Jonge¹, ¹Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, ²Public Health, Erasmus Medical center, Rotterdam, Netherlands, ³Department of Paediatric Immunology, University Medical Centre Utrecht, Netherlands, ⁴Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: Methotrexate (MTX) is the most commonly used drug in rheumatoid arthritis (RA). 30% of patients fail to respond to the drug or suffer from…
Abstract Number: 232 • 2012 ACR/ARHP Annual Meeting
The Natural History of Sporadic Inclusion Body Myositis – an Observational Longitudinal Study
Pedro Machado¹, Andrea Cortese¹, Jasper Morrow¹, Liz Dewar¹, Andy Hiscock¹, Adrian Miller¹, Stefen Brady², David Hilton-Jones², Matt Parton¹ and Michael G. Hanna¹, ¹MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, United Kingdom, ²Oxford Muscle and Nerve Centre, John Radcliffe Hospital, Oxford, United Kingdom
Background/Purpose: Our aim was to assess prospectively the clinical features and functional impact of inclusion body myositis (IBM), to identify reliable outcome measures for future…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].